Citigroup gives Biohaven (BHVN.US) a "buy" rating and is optimistic about the potential of its core drug riluzole being approved by the FDA.

Zhtng cijng APP huxn, Biohaven (BHVN.US) hxn qdng yns ziy zhyo zci ql zu (troriluzole) yubi qinzhng hud FDA pngdng gi yow mngqin zhng chsn shng, huq ynhng giy gi g mir pngj bng shdng mi g 28 miyun mbio ji.